Methodological issues in undertaking independent cost-effectiveness analysis for NICE: The case of therapies for ADHD

European Journal of Health Economics

Volumn 9, Issue 2, 2008, Pages 137-145

  Griffin, Susan C ^a   Weatherly, Helen L A ^a   Richardson, Gerry A ^a   Drummond, Mike F ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

Author keywords

ADHD; Cost effectiveness analysis; Decision making; Guidelines; NICE

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; COST EFFECTIVENESS ANALYSIS; ECONOMIC ASPECT; ECONOMIC EVALUATION; HUMAN; METHODOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BEHAVIOR THERAPY; CENTRAL NERVOUS SYSTEM STIMULANTS; COST-BENEFIT ANALYSIS; DECISION MAKING; DEXTROAMPHETAMINE; EVIDENCE-BASED MEDICINE; GREAT BRITAIN; GUIDELINES AS TOPIC; HUMANS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SICKNESS IMPACT PROFILE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 42149180136     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-007-0052-7     Document Type: Article

References (17)

1. Drummond M.F., Sculpher M.J., TorranceG.W., O'Brien B.J., Stoddart G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
2. NICE. National Institute for Health and Clinical Excellence: Guide to the Technology Appraisal Process. London (2004)
3. Canadian Coordinating Office for Health Technology Assessment (CCOHTA): Guidelines for Authors of CCOHTA Health Technology Assessment Reports, Ottawa (2003)
4. Pharmaceutical Management Agency Ltd (PHARMAC): A Prescription for Pharmacoeconomic Analysis. Wellington: Pharmaceutical Management Agency; Report No.: Version 1.1 (2004)
5. NICE National Institute for Health and Clinical Excellence: Guide to the methods of technology appraisal. London (2004)
6. King, S., Griffin, S., Hodges, Z., Weatherly, H., Asseburg, C., Richardson, G., et al.: Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children. Health Technol Assess 10(23):1-162 (2006)
7. Gold, M. R., Siegel, J. E., Russell, L. B., Weinstein, M. C.: Cost-effectiveness in health and medicine. Oxford University Press, Oxford (1996)
8. NICE. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents including review of existing guidance number 13 (Guidance on the use of methylphenidate [Ritalin, Equasym] for Attention Deficit/Hyperactivity Disorder [ADHD] in childhood): Scope. London: National Institute for Health and Clinical Excellence (2003)
9. Hawkins, N., Epstein, D., Drummond, M., Wilby, J., Kainth, A., Chadwick, D., et al.: Assessing the cost-effectiveness of new pharmaceuticals in epilepsy in adults: The results of a probabilistic decision model. Med Decis Making 25(5):493-511 (2005)
10. Ades, A. E., Cliffe, S.: Markov Chain Monte Carlo estimation of a multi-parameter decision model: consistency of evidence and the accurate assessment of uncertainty. Med Decis Making 22:359-371 (2002)
11. Higgins, J. P. T., Whitehead, A.: Borrowing strength from external trials in a meta-analysis. Stats in Med 15:2733-2749 (1996)
12. Ades, A. E., Sculpher, M., Sutton, A., Abrams, K., Cooper, N., Welton, N., et al.: Bayesian methods for evidence synthesis in cost-effectiveness analysis Pharmacoeconomics 24(1):1-19 (2006)
13. Caldwell, D. M., Ades, A. E., Higgins, J. P. T.: Simultaneous comparison of multiple treatments: combining direct and indirect evidence. Biol Med 97-900 (2005)
14. Janssen-Cilag Ltd. For Health Technology Appraisal: Methylphenidate, atomoxetine and dexamphetamine for attention-deficit/hyperactivity disorder in children and adolescents, including review of existing guidance number 13. A submission to the National Institute for Clinical Excellence. Bucks: Janssen-Cilag (2004)
15. Coghill, D., Spender, Q., BArton, J., Hollis, C., Yuen, C., Cleemput, I.: Measuring quality of life in children with attention-deficit-hyperactivity- disorder in the United Kingdom. In: 16th World Congress of the International Association of Child and Adolescent Psychiatry and Allied Professions (IACAPAP); 2004; Germany (2004)
16. Eli Lilly and Company Ltd. Atomoxetine for the treatment of ADHD. A submission to the National Institute for Clinical Excellence. Hampshire: Eli Lilly and Company (2004)
17. Secnik, K., Cottrell, S., Matza, L. S., Edgell, E., Aristides, M., Tilden, D.: Assessment of health state utilities for attention-deficit/ hyperactivity disorder in children using parent-based standard gamble scores. In: 9th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR); 2004; Arlington (2004)